{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:11:11Z","timestamp":1782843071924,"version":"3.54.5"},"reference-count":155,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2019,12,7]],"date-time":"2019-12-07T00:00:00Z","timestamp":1575676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union \u2013 the European Regional Development Fund","award":["Operational Program \u201cInnovative economy\u201d for 2007\u20132013"],"award-info":[{"award-number":["Operational Program \u201cInnovative economy\u201d for 2007\u20132013"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Percutaneous coronary interventions with stent-based restorations of vessel patency have become the gold standard in the treatment of acute coronary states. Bioresorbable vascular scaffolds (BVS) have been designed to combine the efficiency of drug-eluting stents (DES) at the time of implantation and the advantages of a lack of foreign body afterwards. Complete resolution of the scaffold was intended to enable the restoration of vasomotor function and reduce the risk of device thrombosis. While early reports demonstrated superiority of BVS over DES, larger-scale application and longer observation exposed major concerns about their use, including lower radial strength and higher risk of thrombosis resulting in higher rate of major adverse cardiac events. Further focus on procedural details and research on the second generation of BVS with novel properties did not allow to unequivocally challenge position of DES. Nevertheless, BVS still have a chance to present superiority in distinctive indications. This review presents an outlook on the available first and second generation BVS and a summary of results of clinical trials on their use. It discusses explanations for unfavorable outcomes, proposed enhancement techniques and a potential niche for the use of BVS.<\/jats:p>","DOI":"10.3390\/jcm8122167","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T05:54:51Z","timestamp":1575870891000},"page":"2167","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Bioresorbable Vascular Scaffolds\u2014Dead End or Still a Rough Diamond?"],"prefix":"10.3390","volume":"8","author":[{"given":"Mateusz P.","family":"Je\u017cewski","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, 02091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142 J.","family":"Kubisa","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, 02091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceren","family":"Eyileten","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, 02091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5388-942X","authenticated-orcid":false,"given":"Salvatore","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Division of Cardiology, \u201cMagna Graecia\u201d University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Christ","sequence":"additional","affiliation":[{"name":"Department of Cardiology, 5th Medical Department with Cardiology, Kaiser Franz Josef Hospital, 31100 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2630-5016","authenticated-orcid":false,"given":"Maciej","family":"Lesiak","sequence":"additional","affiliation":[{"name":"1st Department of Cardiology, Poznan University of Medical Sciences, 1061701 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Indolfi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Division of Cardiology, \u201cMagna Graecia\u201d University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2522-3887","authenticated-orcid":false,"given":"Aurel","family":"Toma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, 231090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, 02091 Warsaw, Poland"},{"name":"Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, 231090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-4458","authenticated-orcid":false,"given":"Marek","family":"Postu\u0142a","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, 02091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/eurheartj\/ehv428","article-title":"Cardiovascular disease in Europe\u2014Epidemiological update 2015","volume":"36","author":"Townsend","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics-2017 Update: A Report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Schmidt, T., and Abbott, J.D. (2018). Coronary Stents: History, Design, and Construction. J. Clin. Med., 7.","DOI":"10.3390\/jcm7060126"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.4244\/EIJ-D-16-00308","article-title":"Four-year polymer biocompatibility and vascular healing profile of a novel ultrahigh molecular weight amorphous PLLA bioresorbable vascular scaffold: An OCT study in healthy porcine coronary arteries","volume":"12","author":"Vahl","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.4244\/EIJ-D-17-00952","article-title":"Device specificity of vascular healing following implantation of bioresorbable vascular scaffolds and bioabsorbable polymer metallic drug-eluting stents in human coronary arteries: The ESTROFA OCT BVS vs. BP-DES study","volume":"14","author":"Gonzalo","year":"2018","journal-title":"EuroIntervention"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.116.021539","article-title":"Bioresorbable Vascular Scaffolds for Coronary Revascularization","volume":"134","author":"Kereiakes","year":"2016","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0140-6736(09)60325-1","article-title":"A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods","volume":"373","author":"Serruys","year":"2009","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.phrs.2016.03.020","article-title":"Bioresorbable vascular scaffolds: Biodegradation, drug delivery and vascular remodeling","volume":"107","author":"Tesfamariam","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1161\/CIRCULATIONAHA.117.028479","article-title":"Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials","volume":"135","author":"Montone","year":"2017","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.7326\/M17-1101","article-title":"Mid- and Long-Term Outcome Comparisons of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis","volume":"167","author":"Zhang","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4244\/EIJ-D-18-00567","article-title":"Bioresorbable vascular scaffolds in coronary chronic total occlusions: Clinical, vasomotor and optical coherence tomography findings at three-year follow-up (ABSORB-CTO study)","volume":"15","author":"Gheorghe","year":"2019","journal-title":"EuroIntervention"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MCA.0000000000000518","article-title":"Bioresorbable vascular scaffolds: Implication of very late scaffold thrombosis","volume":"28","author":"Mori","year":"2017","journal-title":"Coron. Artery Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.jcin.2017.08.025","article-title":"Bioresorbable Vascular Scaffolds Restenosis: Pathophysiology and Predictors","volume":"10","author":"Alfonso","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"De Rosa, S., and Indolfi, C. (2015). Letter by De Rosa and Indolfi regarding article, \u201cClinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations\u201d. Circ. Cardiovasc. Interv., 8.","DOI":"10.1161\/CIRCINTERVENTIONS.115.002375"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1161\/CIRCIMAGING.114.001727","article-title":"Neointimal proliferation is associated with clinical restenosis 2 years after fully bioresorbable vascular scaffold implantation","volume":"7","author":"Indolfi","year":"2014","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4244\/EIJV9I11A217","article-title":"Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: A multi-imaging modality study at 6, 12, 24 and 36 months","volume":"9","author":"Serruys","year":"2014","journal-title":"EuroIntervention"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","article-title":"Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): A 3 year, randomised, controlled, single-blind, multicentre clinical trial","volume":"388","author":"Serruys","year":"2016","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4244\/EIJ-D-17-00873","article-title":"Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)","volume":"13","author":"Chevalier","year":"2018","journal-title":"EuroIntervention"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1614954","article-title":"Bioresorbable Scaffolds versus Metallic Stents in Routine PCI","volume":"376","author":"Wykrzykowska","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"903","DOI":"10.21037\/jtd.2017.06.34","article-title":"Magmaris: A new generation metallic sirolimus-eluting fully bioresorbable scaffold: Present status and future perspectives","volume":"9","author":"Rapetto","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(12)61765-6","article-title":"Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial","volume":"381","author":"Haude","year":"2013","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1093\/eurheartj\/ehw196","article-title":"Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial","volume":"37","author":"Haude","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.4244\/EIJ-D-15-00371","article-title":"Safety and performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in patients with de novo coronary lesions: 3-year results of the prospective, multicentre, first-in-man BIOSOLVE-I trial","volume":"12","author":"Haude","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4244\/EIJ-D-17-00254","article-title":"Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: Pooled outcomes of BIOSOLVE-II and BIOSOLVE-III","volume":"13","author":"Haude","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_25","unstructured":"Verheye, S., Wlodarczak, A., Montorsi, P., Bennett, J., Torzewski, J., and Haude, M. (2019). Safety and performance of a resorbable magnesium scaffold under real-world conditions: 12-month outcomes of the first 400 patients enrolled in the BIOSOLVE-IV registry. EuroIntervention."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/joic.12415","article-title":"Clinical and angiographic outcome of a single center, real world population treated with a dedicated technique of implantation for bioresorbable vascular scaffolds. The FAtebenefratelli Bioresorbable Vascular Scaffold (FABS) registry","volume":"30","author":"Cortese","year":"2017","journal-title":"J. Interv. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3349\/ymj.2017.58.5.1071","article-title":"Optical Coherence Tomography and Stent Boost Imaging Guided Bioresorbable Vascular Scaffold Overlapping for Coronary Chronic Total Occlusion Lesion","volume":"58","author":"Li","year":"2017","journal-title":"Yonsei Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijcard.2016.07.033","article-title":"Optical coherence tomography guidance for percutaneous coronary intervention with bioresorbable scaffolds","volume":"221","author":"Caiazzo","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijcard.2015.07.101","article-title":"Absorb bioresorbable vascular scaffold: What have we learned after 5 years of clinical experience?","volume":"201","author":"Caiazzo","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jcin.2013.05.017","article-title":"Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: The ABSORB cohort A trial","volume":"6","author":"Onuma","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ehj.2016.07.002","article-title":"Bioresorbable vascular scaffold (BVS) for the treatment of native coronary artery stenosis: One year outcome","volume":"68","author":"Khamis","year":"2016","journal-title":"Egypt. Heart J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.113.001790","article-title":"Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans","volume":"129","author":"Otsuka","year":"2014","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1161\/CIRCINTERVENTIONS.110.958249","article-title":"Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation","volume":"3","author":"Yamaji","year":"2010","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"887","DOI":"10.21037\/jtd.2017.06.59","article-title":"Effectiveness and safety of the ABSORB bioresorbable vascular scaffold for the treatment of coronary artery disease: Systematic review and meta-analysis of randomized clinical trials","volume":"9","author":"Pavasini","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/CIRCULATIONAHA.110.971606","article-title":"Bioresorbable scaffold: The advent of a new era in percutaneous coronary and peripheral revascularization?","volume":"123","author":"Onuma","year":"2011","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"24492","DOI":"10.3390\/ijms141224492","article-title":"Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease","volume":"14","author":"Campos","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"979","DOI":"10.21037\/jtd.2017.07.104","article-title":"New generation bioresorbable scaffold technologies: An update on novel devices and clinical results","volume":"9","author":"Regazzoli","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4244\/EIJ-D-16-00915","article-title":"Second-generation magnesium scaffold Magmaris: Device design and preclinical evaluation in a porcine coronary artery model","volume":"13","author":"Waksman","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/MDER.S90461","article-title":"Bioresorbable vascular scaffolds technology: Current use and future developments","volume":"9","author":"Giacchi","year":"2016","journal-title":"Med. Devices"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijcard.2014.09.143","article-title":"Impact of stent strut design in metallic stents and biodegradable scaffolds","volume":"177","author":"Foin","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E741","DOI":"10.21037\/jtd.2016.05.80","article-title":"Bioresorbable vascular scaffolds\u2014What does the future bring?","volume":"8","author":"Bil","year":"2016","journal-title":"J. Thorac. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"734","DOI":"10.4244\/EIJ-D-17-00499","article-title":"State of the art: The inception, advent and future of fully bioresorbable scaffolds","volume":"13","author":"Katagiri","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1040","DOI":"10.4244\/EIJ-D-17-00708","article-title":"Preclinical evaluation of degradation kinetics and elemental mapping of first- and second-generation bioresorbable magnesium scaffolds","volume":"14","author":"Joner","year":"2018","journal-title":"EuroIntervention"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1161\/CIRCULATIONAHA.112.097014","article-title":"Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: A mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials","volume":"125","author":"Bangalore","year":"2012","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Cassese, S., Katagiri, Y., Byrne, R.A., Brugaletta, S., Alfonso, F., and R\u00e4ber, L. (2019). Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents. A pooled analysis of individual patient data from 2 randomized trials. EuroIntervention.","DOI":"10.4244\/EIJ-D-18-01080"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4244\/EIJ-D-16-00253","article-title":"Everolimus-eluting bioresorbable vascular scaffolds for treatment of complex chronic total occlusions","volume":"13","author":"Chisari","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/j.jacc.2015.09.030","article-title":"Systemic Pharmacokinetics of Everolimus Eluted from the Absorb Bioresorbable Vascular Scaffold: An ABSORB III Substudy","volume":"66","author":"Chisari","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.4244\/EIJ-D-17-00716","article-title":"Multislice computed tomography assessment of everolimus-eluting Absorb bioresorbable scaffolds in comparison with metallic drug-eluting stents from the ABSORB Japan randomised trial","volume":"14","author":"Tanabe","year":"2018","journal-title":"EuroIntervention"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ijcard.2016.11.258","article-title":"Bioresorbable stents: Current and upcoming bioresorbable technologies","volume":"228","author":"Ang","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(17)31470-8","article-title":"2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: A systematic review and meta-analysis of seven randomised trials with an individual patient data substudy","volume":"390","author":"Ali","year":"2017","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/1526602817698935","article-title":"Lessons Learned Regarding Handling and Deployment of the Absorb Bioresorbable Vascular Scaffold in Infrapopliteal Arteries","volume":"24","author":"Varcoe","year":"2017","journal-title":"J. Endovasc. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Sorrentino, S., De Rosa, S., Ambrosio, G., Mongiardo, A., Spaccarotella, C., Polimeni, A., Jolanda, S., Daniele, T., Gianluca, C., and Ciro, I. (2015). The duration of balloon inflation affects the luminal diameter of coronary segments after bioresorbable vascular scaffolds deployment. BMC Cardiovasc. Disord., 15.","DOI":"10.1186\/s12872-015-0163-5"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"950","DOI":"10.21037\/jtd.2017.07.25","article-title":"The DESolve novolimus bioresorbable Scaffold: From bench to bedside","volume":"9","author":"Mattesini","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2016.11.033","article-title":"A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives","volume":"227","author":"Nef","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jcin.2015.12.004","article-title":"Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions","volume":"9","author":"Abizaid","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4244\/EIJY15M02_03","article-title":"An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8\/Xpedition)","volume":"11","author":"Ormiston","year":"2015","journal-title":"EuroIntervention"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.carrev.2016.05.001","article-title":"In vitro performance investigation of bioresorbable scaffolds - Standard tests for vascular stents and beyond","volume":"17","author":"Schmidt","year":"2016","journal-title":"Cardiovasc. Revasc. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcin.2013.07.007","article-title":"A next-generation bioresorbable coronary scaffold system: From bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results","volume":"7","author":"Verheye","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"de Pommereau, A., de Hemptinne, Q., Varenne, O., and Picard, F. (2018). Bioresorbable vascular scaffolds: Time to absorb past lessons or fade away?. Arch. Cardiovasc. Dis.","DOI":"10.1016\/j.acvd.2018.04.001"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)00447-X","article-title":"Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial","volume":"387","author":"Haude","year":"2016","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4244\/JV4I4A82","article-title":"Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents","volume":"4","author":"Ghimire","year":"2009","journal-title":"EuroIntervention"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00392-018-1252-0","article-title":"Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents","volume":"107","author":"Varenhorst","year":"2018","journal-title":"Clin. Res. Cardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jbm.b.31918","article-title":"Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells in vitro","volume":"100","author":"Sternberg","year":"2012","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00005344-200307000-00004","article-title":"Effect of magnesium on mRNA expression and production of endothelin-1 in DOCA-salt hypertensive rats","volume":"42","author":"Berthon","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_66","unstructured":"Kereiakes, D.J., and Ellis, S.G. (2017). 3-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. J. Am. Coll. Cardiol."},{"key":"ref_67","unstructured":"Ellis, S.G., and Kereiakes, D.J. (2017). Everolimus-Eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results, American College of Cardiology Annual Scientific Session."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S0140-6736(18)32283-9","article-title":"Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial","volume":"392","author":"Stone","year":"2018","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2017.05.053","article-title":"Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial","volume":"243","author":"Arroyo","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e1224","DOI":"10.4244\/EIJ-D-18-00839","article-title":"Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)","volume":"14","author":"Katagiri","year":"2018","journal-title":"EuroIntervention"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1093\/eurheartj\/ehv435","article-title":"A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan","volume":"36","author":"Kimura","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jacc.2015.11.060","article-title":"A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up","volume":"67","author":"Serruys","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4244\/EIJV12I1A5","article-title":"Long-term follow-up after bioresorbable vascular scaffold implantation in STEMI patients: PRAGUE-19 study update","volume":"12","author":"Kozel","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.4244\/EIJ-D-17-00796","article-title":"Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: Three-year clinical outcomes from the ABSORB China randomised trial","volume":"14","author":"Xu","year":"2018","journal-title":"EuroIntervention"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/eurheartj\/ehy710","article-title":"Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: The Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial","volume":"40","author":"Byrne","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jacc.2017.09.418","article-title":"TCT-330 Multi-Center Evaluation of a Novel 120 \u03bcm Novolimus-Eluting, Fully Bioresorbable Coronary Scaffold: First Report of 6-month Imaging and 12-Month Clinical Results","volume":"70","author":"Abizaid","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/ccd.27550","article-title":"A multicenter post-marketing evaluation of the Elixir DESolve((R)) Novolimus-eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study","volume":"92","author":"Nef","year":"2018","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0735-1097(16)30233-9","article-title":"Initial results of the fantom 1 trial: A first-in-man evaluation of a novel, radiopaque sirolimus-eluting bioresorbable vascular scaffold","volume":"67","author":"Abizaid","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jcin.2017.07.033","article-title":"6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study","volume":"10","author":"Abizaid","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e557","DOI":"10.4244\/EIJV12I5A95","article-title":"Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria","volume":"12","author":"Kraak","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jacc.2014.12.017","article-title":"Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds","volume":"65","author":"Puricel","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jcin.2017.06.009","article-title":"Fantom Bioresorbable Scaffold: Verse, But Not Yet Chorus (An Incomplete Composition)","volume":"10","author":"Ellis","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jcin.2017.11.042","article-title":"Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis: Multistudy Registry Results","volume":"11","author":"Ellis","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jcin.2018.01.272","article-title":"Bioresorbable Vascular Scaffolds: Back to the Drawing Board","volume":"11","author":"Mahmud","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jcin.2016.03.027","article-title":"The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial","volume":"9","author":"Suwannasom","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"42","DOI":"10.14797\/mdcj-14-1-42","article-title":"Bioresorbable Coronary Scaffolds: Deployment Tips and Tricks and the Future of the Technology","volume":"14","author":"Costa","year":"2018","journal-title":"Methodist DeBakey Cardiovasc. J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4244\/EIJV10I6A118","article-title":"Comparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: An exploratory observational study prior to a randomised trial","volume":"10","author":"Zhang","year":"2014","journal-title":"EuroIntervention"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2017.05.028","article-title":"Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents","volume":"70","author":"Serruys","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/ccd.26148","article-title":"Does optimal lesion preparation reduce the amount of acute recoil of the Absorbe BVS? Insights from a real-world population","volume":"86","author":"Danzi","year":"2015","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.4244\/EIJY16M09_01","article-title":"Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: Insights from the randomised ABSORB Japan trial","volume":"12","author":"Onuma","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Kochman, J., Tomaniak, M., J\u0105ka\u0142a, J., Proniewska, K., Legutko, J., and Roleder, T. (2017). First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second generation ABSORB bioresorbable vascular scaffold. EuroIntervention.","DOI":"10.4244\/EIJ-D-17-00311"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4244\/EIJV5IFA3","article-title":"Design principles and performance of bioresorbable polymeric vascular scaffolds","volume":"5","author":"Oberhauser","year":"2009","journal-title":"EuroIntervention"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Ortega-Paz, L., Brugaletta, S., and Sabat\u00e9, M. (2018). Impact of PSP Technique on Clinical Outcomes Following Bioresorbable Scaffolds Implantation. J. Clin. Med., 7.","DOI":"10.3390\/jcm7020027"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"374","DOI":"10.5603\/CJ.a2016.0052","article-title":"Impact of postdilatation on performance of bioresorbable vascular scaffolds in patients with acute coronary syndrome compared with everolimus-eluting stents: A propensity score-matched analysis from a multicenter \u201creal-world\u201d registry","volume":"23","author":"Imori","year":"2016","journal-title":"Cardiol. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.jcin.2017.07.035","article-title":"Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy","volume":"10","author":"Yamaji","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.jacc.2017.09.1106","article-title":"Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis from the ABSORB Trials","volume":"70","author":"Stone","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Polimeni, A., Anadol, R., M\u00fcnzel, T., Geyer, M., De Rosa, S., Indolfi, C., and Gori, T. (2019). Bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A meta-analysis. BMC Cardiovasc. Disord., 19.","DOI":"10.1186\/s12872-019-1042-2"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11886-017-0836-z","article-title":"Bioresorbable Scaffolds for Coronary Stenosis: When and How Based Upon Current Studies","volume":"19","author":"Abizaid","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jcin.2016.12.013","article-title":"Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry","volume":"10","author":"Geraci","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e550","DOI":"10.4244\/EIJY15M09_10","article-title":"Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: Insights from the GHOST-EU registry","volume":"12","author":"Gori","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(15)00979-4","article-title":"Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: A meta-analysis of randomised controlled trials","volume":"387","author":"Cassese","year":"2016","journal-title":"Lancet"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","article-title":"1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: A patient-level, pooled meta-analysis","volume":"387","author":"Stone","year":"2016","journal-title":"Lancet"},{"key":"ref_103","first-page":"32","article-title":"Early, late and very late incidence of bioresorbable scaffold thrombosis: A systematic review and meta-analysis of randomized clinical trials and observational studies","volume":"65","author":"MiYaZaKi","year":"2017","journal-title":"Minerva Cardioangiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcin.2015.09.024","article-title":"Scaffold Thrombosis After Percutaneous Coronary Intervention with ABSORB Bioresorbable Vascular Scaffold: A Systematic Review and Meta-Analysis","volume":"9","author":"Lipinski","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.4244\/EIJ-D-17-00646","article-title":"Long-term safety of bioresorbable scaffolds: Insights from a network meta-analysis including 91 trials","volume":"13","author":"Kang","year":"2018","journal-title":"EuroIntervention"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.4244\/EIJV12I2A28","article-title":"One-year outcomes after Absorb bioresorbable vascular scaffold implantation in routine clinical practice","volume":"12","author":"Capranzano","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4244\/EIJY14M07_11","article-title":"Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry","volume":"10","author":"Capodanno","year":"2015","journal-title":"EuroIntervention"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/ccd.26346","article-title":"Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry","volume":"87","author":"Hoppmann","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ccd.26569","article-title":"Bioresorbable vascular scaffold thrombosis in a consecutive cohort of 550 patients","volume":"88","author":"Achenbach","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jcin.2014.12.244","article-title":"Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes","volume":"8","author":"Gori","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.4244\/EIJY14M08_08","article-title":"Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: The AMC Single Centre Real World PCI Registry","volume":"10","author":"Kraak","year":"2015","journal-title":"EuroIntervention"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e002933","DOI":"10.1161\/CIRCINTERVENTIONS.115.002933","article-title":"One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: The PRAGUE-19 Study","volume":"8","author":"Widimsky","year":"2015","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.4244\/EIJV12I2A27","article-title":"Percutaneous coronary intervention for chronic total occlusion of the coronary artery with the implantation of bioresorbable everolimus-eluting scaffolds. Poznan CTO-Absorb Pilot Registry","volume":"12","author":"Hoye","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_114","first-page":"316","article-title":"Twelve-Month Outcomes with a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers","volume":"28","author":"Robaei","year":"2016","journal-title":"J. Invasive Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4244\/EIJY15M01_05","article-title":"Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: A European perspective","volume":"11","author":"Tamburino","year":"2015","journal-title":"EuroIntervention"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.jcin.2016.08.019","article-title":"The Nidus for Possible Thrombus Formation: Insight from the Microenvironment of Bioresorbable Vascular Scaffold","volume":"9","author":"Tenekecioglu","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jcin.2014.01.165","article-title":"ABSORB biodegradable stents versus second-generation metal stents: A comparison study of 100 complex lesions treated under OCT guidance","volume":"7","author":"Mattesini","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcin.2014.10.005","article-title":"Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: The BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction)","volume":"8","author":"Brugaletta","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4244\/EIJY14M12_10","article-title":"Beyond the early stages: Insights from the ASSURE registry on bioresorbable vascular scaffolds","volume":"11","author":"Naber","year":"2015","journal-title":"EuroIntervention"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/eurheartj\/ehv500","article-title":"Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: Results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial","volume":"37","author":"Windecker","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.thromres.2013.05.029","article-title":"Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: The blocking and bridging strategy","volume":"132","author":"Christ","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.amjcard.2015.12.025","article-title":"One-Year Results of Bioresorbable Vascular Scaffolds for Coronary Chronic Total Occlusions","volume":"117","author":"Vaquerizo","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2015.02.048","article-title":"Outcomes and computed tomography scan follow-up of bioresorbable vascular scaffold for the percutaneous treatment of chronic total coronary artery occlusion","volume":"115","author":"Ojeda","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ccd.27388","article-title":"Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: A subanalysis of the European Multicentre GHOST-EU Registry","volume":"91","author":"Capranzano","year":"2018","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/CIRCINTERVENTIONS.111.967083","article-title":"Stent thrombosis with everolimus-eluting stents: Meta-analysis of comparative randomized controlled trials","volume":"5","author":"Palmerini","year":"2012","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Authors\/Task Force members, Windecker, S., Kolh, P., Alfonso, F., Collet, J.P., Cremer, J., and J\u00fcni, P. (2014). 2014 ESC\/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J., 35, 2541\u20132619.","DOI":"10.1093\/eurheartj\/ehu278"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e002230","DOI":"10.1161\/CIRCINTERVENTIONS.114.002230","article-title":"Comparison of zotarolimus- and everolimus-eluting coronary stents: Final 5-year report of the RESOLUTE all-comers trial","volume":"8","author":"Iqbal","year":"2015","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.4244\/EIJ-D-17-00309","article-title":"How should I treat a bioresorbable vascular scaffold edge restenosis and intra-scaffold dissection?","volume":"13","author":"Fallesen","year":"2018","journal-title":"EuroIntervention"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4244\/EIJV13I7A115","article-title":"Bioresorbable scaffolds: Reflections after a setback\u2014Losing a battle does not mean losing the war!","volume":"13","author":"Colombo","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","article-title":"Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis","volume":"370","author":"Stettler","year":"2007","journal-title":"Lancet"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.107.693739","article-title":"Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization","volume":"115","author":"FinnAV","year":"2007","journal-title":"Circulation"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/ATVBAHA.107.144220","article-title":"Vascular responses to drug eluting stents: Importance of delayed healing","volume":"27","author":"Finn","year":"2007","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk","volume":"48","author":"Joner","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e011245","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Beckman, J.A., and White, C.J. (2019). Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients with Peripheral Artery Disease?. Circulation.","DOI":"10.1161\/CIRCULATIONAHA.119.041099"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/14779072.2018.1473034","article-title":"Imaging-guided pre-dilatation, stenting, post-dilatation: A protocolized approach highlighting the importance of intravascular imaging for implantation of bioresorbable scaffolds","volume":"16","author":"Ali","year":"2018","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.4244\/EIJ-D-16-00974","article-title":"Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: Development and internal validation of the PSP score","volume":"12","author":"Capodanno","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/joic.12392","article-title":"Long-term clinical results of bioresorbable absorb scaffolds using the PSP-technique in patients with and without diabetes","volume":"30","author":"Markovic","year":"2017","journal-title":"J. Interv. Cardiol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Heeger, C.H., Schedifka, A.S., Meincke, F., Spangenberg, T., Wienemann, H., and Kreidel, F. (2018). Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry. Cardiol. J.","DOI":"10.5603\/CJ.a2018.0021"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"von Zur M\u00fchlen, C., Reiss, S., Krafft, A.J., Besch, L., Menza, M., Zehender, M., and Rein\u00f6hl, J. (2018). Coronary magnetic resonance imaging after routine implantation of bioresorbable vascular scaffolds allows non-invasive evaluation of vascular patency. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0191413"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4070\/kcj.2017.0194","article-title":"Bioresorbable Scaffolds in Coronary Intervention: Unmet Needs and Evolution","volume":"48","author":"Capodanno","year":"2018","journal-title":"Korean Circ. J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.actbio.2015.08.009","article-title":"Degree of bioresorbable vascular scaffold expansion modulates loss of essential function","volume":"26","author":"Ferdous","year":"2015","journal-title":"Acta Biomater."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.4244\/EIJV12I5A96","article-title":"Absorb vs. DESolve: An optical coherence tomography comparison of acute mechanical performances","volume":"12","author":"Mattesini","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study","volume":"382","author":"Stone","year":"2013","journal-title":"Lancet"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jcin.2013.06.011","article-title":"Response variability to P2Y12 receptor inhibitors: Expectations and reality","volume":"6","author":"Trenk","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jcin.2012.01.009","article-title":"A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: Results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study","volume":"5","author":"Mangiacapra","year":"2012","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/eurheartj\/ehx488","article-title":"Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: Executive summary","volume":"39","author":"Byrne","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e005781","DOI":"10.1136\/bmjopen-2014-005781","article-title":"Individualising dual antiplatelet therapy after percutaneous coronary intervention: The IDEAL-PCI registry","volume":"4","author":"Christ","year":"2014","journal-title":"BMJ Open"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1042\/CS20140310","article-title":"The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention","volume":"128","author":"Gruber","year":"2015","journal-title":"Clin. Sci."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ijcard.2012.05.040","article-title":"Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study","volume":"167","author":"Francesconi","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.vph.2016.01.003","article-title":"Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor","volume":"79","author":"Hintermeier","year":"2016","journal-title":"Vascul. Pharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1160\/TH13-03-0250","article-title":"Why have studies of tailored anti-platelet therapy failed so far?","volume":"110","author":"Jilma","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/TCRM.S152369","article-title":"Ticagrelor\u2014Toward more efficient platelet inhibition and beyond","volume":"14","author":"Kubisa","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ccd.27196","article-title":"TIcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGER-BVS trial): Rationale and study design","volume":"91","author":"Brugaletta","year":"2018","journal-title":"Catheter. Cardiovasc. Interv."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/12\/2167\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:40:18Z","timestamp":1760190018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/12\/2167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,7]]},"references-count":155,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["jcm8122167"],"URL":"https:\/\/doi.org\/10.3390\/jcm8122167","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,7]]}}}